Annual, English, IR, Listing Regulation, News, Regulatory, Report

Acarix AB’s Annual Report 2025

  • Posted by author-avatar
15 Apr

Acarix, a global leader in AI and advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2025 is available as a pdf on the company’s website,

https://acarix.com/financial-reports-and-calendar/
The Annual Report is available in Swedish and English.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 60,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). The Company’s Certified Adviser is Tapper Partners AB. For more information, please visit www.acarix.com

For more information, contact
Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments
Acarix English Annual 2025 Report Final

Acarix English Annual 2025 Report Final
Back to list
Older Acarix AB’s Årsredovisning 2025